Iressa
Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC
June 20, 2016Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer
Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
AstraZeneca receives US approval for Iressa
July 16, 2015Medical Communications, Sales and Marketing AstraZeneca, FDA, Iressa, lung cancer, non-small cell lung cancer
AstraZeneca’s lung cancer therapy Iressa has been approved by the FDA – four years after the company pulled it from the …
FDA grants AstraZeneca immune drug orphan status
April 15, 2015Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab
The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …
Retrospective study backs Iressa use in oesophageal cancer
November 5, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Cancer Oesophagus Gefitinib, Iressa, gefitinib, oncology
A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …
Giotrif increases lung cancer survival
May 16, 2014Research and Development, Sales and Marketing Boehringer, Iressa, Roche, Tarceva, afatinib, giotrif, lung cancer
Boehringer Ingelheim is trumpeting overall survival results from a new analysis of two late-stage studies involving Giotrif in lung cancer …
Discount sways NICE into recommending Tarceva
May 10, 2012Sales and Marketing Iressa, NICE, NSCLC, Roche, Tarceva, lung cancer
NICE is recommending Roche’s lung cancer pill Tarceva in patients with a certain type of the disease. The watchdog said …
Merck re-submits Erbitux to the EMA for lung cancer
March 30, 2011Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer
Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
AZ and Pfizer support personalised medicine database
February 8, 2011Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine
AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …
Tarceva set for first line treatment
January 31, 2011Sales and Marketing Iressa, NSCLC, Roche, Tarceva
Roche’s lung cancer treatment Tarceva has been shown to help patients as a first line treatment. An independent data monitoring …
NICE approves trio of cancer drugs
July 28, 2010Sales and Marketing Iressa, MabThera, NICE, Xeloda
NICE has given its final recommendation to a trio of drugs for the treatment of various cancers, which means the …
AstraZeneca continues personalised healthcare push
January 19, 2010Sales and Marketing AstraZeneca, Dako, Diagnostics, Iressa
AstraZeneca and cancer diagnostics specialist Dako Denmark are to develop companion diagnostics for a number of the pharma company’s oncology …
AZ’s Iressa to make comeback
April 28, 2009Research and Development, Sales and Marketing AZ, Iressa
AstraZeneca's Iressa is set to make a comeback after a European committee recommended its use for a sub-group of lung …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
